115 related articles for article (PubMed ID: 10656342)
1. An effective vaccine against Lyme disease.
Crooy P; Lobet Y
J Biotechnol; 2000 Jan; 76(2-3):261-3. PubMed ID: 10656342
[No Abstract] [Full Text] [Related]
2. Vaccination as a modality to prevent Lyme disease. A status report.
Wormser GP
Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
[TBL] [Abstract][Full Text] [Related]
3. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
4. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
Wallich R; Kramer MD; Simon MM
Infection; 1996; 24(5):396-7. PubMed ID: 8923055
[No Abstract] [Full Text] [Related]
5. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
6. [Lyme borreliosis--vaccines in the "pipeline"].
Kramer M
MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
[No Abstract] [Full Text] [Related]
7. Lyme arthritis: lessons learned and to be learned.
Sigal LH
Arthritis Rheum; 1999 Sep; 42(9):1809-12. PubMed ID: 10513793
[No Abstract] [Full Text] [Related]
8. Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.
Hebert D; Eschner A
Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960414
[TBL] [Abstract][Full Text] [Related]
9. Immunization against Lyme disease--an important first step.
Steigbigel RT; Benach JL
N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
[No Abstract] [Full Text] [Related]
10. Availability of Lyme disease vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
12. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
Sigal LH
J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
[No Abstract] [Full Text] [Related]
13. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
15. Lyme disease vaccine safe for all?
Rahn DW
Postgrad Med; 1999 Jun; 105(7):21. PubMed ID: 10376044
[No Abstract] [Full Text] [Related]
16. Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.
Nayak A; Schüler W; Seidel S; Gomez I; Meinke A; Comstedt P; Lundberg U
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31932330
[TBL] [Abstract][Full Text] [Related]
17. The ABCs of Lyme disease spirochaetes in ticks.
Munderloh UG; Kurtti TJ
Lancet; 2005 Sep 17-23; 366(9490):962-4. PubMed ID: 16168758
[No Abstract] [Full Text] [Related]
18. Detection of Lyme disease after OspA vaccine.
Schutzer SE; Luan J; Coyle PK
N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
[No Abstract] [Full Text] [Related]
19. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity elicited by rBCG vaccines.
Stover CK; Bansal GP; Langerman S; Hanson MS
Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
